Peter Meldrum
Myriad Genetics' former CEO Peter Meldrum passed away on Dec. 20, 2018, at the age of 71.
Meldrum co-founded Myriad in 1992 with Mark Skolnick, and led the company through many milestones, including its public offering in 1995, the launch of the flagship BRACAnalysis test, the acquisitions of Myriad RBM and Crescendo Bioscience, and the firm's expansion outside the US. By the time he retired in 2015, Myriad had grown to employ 2,500 people and had performed more than 2 million genetic tests.
After his retirement, Meldrum was the executive director of The Meldrum Foundation, his family's private charitable foundation that supports educational, artistic, and humanitarian programs. He was also chairman of the board of directors for Golden Pine Ventures, a biotech-focused venture capital firm.
Meldrum was born in 1947 in Salt Lake City, Utah. In 1970, he received his Bachelor of Science degree in chemical engineering from the University of Utah, and four years later received his MBA from the same institution. Westminster College awarded him an honorary Doctorate of Science in 2004 and the University of Utah gave him an honorary Doctorate of Engineering degree in 2009. Scientific American in 2002 selected him as one of the Top 50 Scientific Visionaries in the World.
Christine Tsingos
Christine Tsingos intends to retire as executive VP and CFO of Bio-Rad, effective April 30, 2019. She has served as CFO for 16 years, during which time the company increased its revenues more than 240 percent and saw an appreciation in its stock price from approximately $30 to a recent high of more than $300 per share. Tsingos will remain in her current role through April 30, and will assist in the transition to a successor.
James Angus McDonald, Tim Cowper
James Angus McDonald has left the board of directors of Oxford Nanopore Technologies as well as the board of its daughter companies, the Genome Foundry and Metrichor, effective Dec. 13, 2018. He had been a director for Oxford Nanopore since 2010, for Metrichor since 2013, and for the Genome Foundry since 2015. McDonald was immediately replaced as director of all three companies by Tim Cowper, Oxford Nanopore's VP of finance. Cowper joined the firm in 2012 and oversees its financial team and strategic supply chain operations. In addition, in November 2018 he was appointed as director of Oxford Nanopore Manufacturing, a new daughter company.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.